Drug Profile
Research programme: type 2 diabetes mellitus fixed combination therapies - Boehringer Ingelheim
Latest Information Update: 25 Oct 2011
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Type 2 diabetes mellitus
Most Recent Events
- 20 Oct 2011 Investigation in Type-2 diabetes mellitus (unspecified route)